Skyhawk news

Browse:

Skyhawk's proprietary platform revolutionizes disease treatment by developing small molecule therapeutics that modify RNA expression

November 12, 2019
Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home
With Bris­tol-My­ers Squibb’s Cel­gene buy­out all but com­plete, the BD teams are work­ing in per­fect syn­chrony now.
Read
2 min read
November 12, 2026
Skyhawk’s $80M Celgene deal expands remit to autoimmune
In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve.
Read
1 min read
November 11, 2019
C&EN’s 2019 10 Start-Ups to Watch
As we at C&EN present our fifth class of 10 Start-Ups to Watch, we can confirm that there are definitely hundreds, and perhaps thousands.
Read
4 min read
November 9, 2019
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene
Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules
Read
2 min read
July 8, 2019
Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster
John Carroll – Editor & Founder What­ev­er Bio­gen learned about Sky­hawk in the 6 months since it an­ted up $74 mil­lion to get a...
Read
2 min read